Hvivo landed its second contract this year with a pharmaceutical company based in Asia Pacific.
The AIM-listed clinical trial specialist has identified the region as a ‘key growth area’.
As part of a £6.8million deal, Hvivo will recruit healthy volunteers to test the client’s antiviral drug for respiratory syncytial virus (RSV).
hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.